BHC(600721)2024-10-24 07:37Financial Performance - Revenue for Q3 2024 was CNY 94,326,850.19, a decrease of 4.24% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 1,292,258.58, down 72.46% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was CNY 563,172.33, a decrease of 86.26% compared to the same period last year[2] - Basic earnings per share for Q3 2024 was CNY 0.0034, down 72.58% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 290.63 million, an increase of 9.36% compared to CNY 265.71 million in the same period of 2023[13] - Net profit attributable to shareholders of the parent company was CNY 23.95 million, up 35.38% from CNY 17.69 million in the first three quarters of 2023[14] - Operating profit increased to CNY 27.14 million, representing a growth of 30.56% compared to CNY 20.77 million in the previous year[13] - Basic earnings per share increased to CNY 0.0627, up from CNY 0.0468 in the first three quarters of 2023[14] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 1,127,279,213.68, an increase of 6.15% from the end of the previous year[3] - The company's total assets as of September 30, 2024, amount to 1,127,279,213.68 RMB, an increase from 1,062,010,154.10 RMB at the end of 2023[11] - The total current assets increased to 617,357,403.06 RMB from 564,767,786.61 RMB[11] - The company's total liabilities as of September 30, 2024, are 387,260,344.89 RMB, compared to 355,394,780.03 RMB at the end of 2023[12] - The company's equity attributable to shareholders increased to 740,018,868.79 RMB from 706,615,374.07 RMB[12] Cash Flow - Cash flow from operating activities for the year-to-date period (January to September 2024) was CNY 60,023,351.85, an increase of 327.86% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of CNY 60.02 million, significantly higher than CNY 14.03 million in the first three quarters of 2023[15] - The company reported a significant increase in cash inflow from operating activities, totaling CNY 305.35 million, compared to CNY 228.91 million in the previous year[15] - Investment activities resulted in a net cash outflow of CNY 163.23 million, compared to a net outflow of CNY 102.04 million in the same period of 2023[16] - Total cash and cash equivalents at the end of the period were CNY 105.22 million, compared to CNY 64.06 million at the end of the same period last year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,523[7] - The largest shareholder, Xinjiang Hualing Industrial Trade (Group) Co., Ltd., holds 79,525,087 shares, accounting for 20.76% of the total shares[8] - The stock option incentive plan resulted in the exercise of 1,129,810 shares, increasing the total share capital to 383,123,080 shares[9] Other Financial Metrics - The weighted average return on net assets for Q3 2024 was 0.18%, a decrease of 0.50 percentage points year-on-year[2] - The company experienced a 100% increase in trading financial assets due to the purchase of bank wealth management products[5] - The company reported a significant increase in prepayments by 72.04% due to increased clinical trial project prepayments[5] - Non-recurring gains and losses totaled CNY 729,086.25 for the year-to-date period, down from CNY 2,251,802.13 in the previous year[4] - Research and development expenses rose to CNY 22.27 million, a 5.03% increase from CNY 21.20 million in the same period last year[13] Strategic Initiatives - The company has initiated new strategies for market expansion and product development, although specific details were not disclosed in the financial report[17]